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Abstract
Background: In 1983, Graham Hughes described a condition of Antiphospholipid Syndrome in
which there was a danger of thrombosis. The condition is readily detectable by blood tests and,
once diagnosed; the risk of further thrombosis can be significantly reduced by anticoagulation
treatments. Affected groups of patients can be distinguished by a specific blood test – the detection
of antiphospholipid antibody (Ref-1). Patients with Hughes syndrome have hypercoaguable state
with a markedly increased risk of both arterial and venous thrombosis and there is temporal
persistence of antibody positivity.
Case presentation: A 44-year-old woman was admitted under the acute surgical "take" with left
sided abdominal pain radiating to her back. She had a history of borderline thyrotoxicosis in the
early 1990s. She was on etonogestrel-releasing implants for contraception and there was no history
of previous deep venous thrombosis. She was very tender, locally, over the left side of the
abdomen. Investigations showed haemoglobin of 13.2 g/dl, white cell count of 19.9 10*9/L, and
platelets 214 10*9/L with neutrophilia. Amylase and renal function tests were found to be normal.
Liver function tests were deranged with Gamma GT 244 u/l (twice normal). An abdominal
Ultrasound Scan suggested a possible splenic infarction, which was confirmed by a CT scan of her
abdomen. Tests were carried out to investigate the possibility of a post thrombotic state.
Coagulation risk factors for thrombosis were within the normal limits; Protein S 67 %(60–140),
Protein C 103 % (72–146), Antithrombin 3 110 %(80–120) and Activated P C Resistance was
1.9(2.0–4.3). The Hams test was negative but the Anticardiolipin antibody test was positive. IgM
level was 52 (normal is up to 10) and IgG was 18.8 (normal is up to 10). She also had border line
APC Sensitivity 1.9 (2 to 4.3). Kaolin time 49 sec (70–120) Ktmix 64 sec (70–120), thyroid function
test revealed TSH 0.32 mu/L, fT4 20.2 pmol/L (10–25). Subsequent determination of Anticardiolipin
antibody was negative. Her symptoms were settled with the use of simple analgesia and she was
discharged home with long-term anticoagulation medication. The INR target for long-term
anticoagulation was aimed at >3.
Conclusion: This case presented to us as an acute abdominal pain. Subsequent investigations
revealed the presence of splenic infarction. Coagulation risk factors for thrombosis proved
negative. Haematological investigations revealed the presence of anticardiolipin antibodies at the
first instance but subsequent determinations were negative. Hence, it mimicked Hughes syndrome
initially but the criteria for temporal persistence of anticardiolipin antibody was not fulfilled.
Unusual surgical presentation of a thrombotic abnormality as abdominal pain due to splenic
infarction.
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Background
In 1983, Graham Hughes described a condition of
Antiphospholipid Syndrome in which there was a danger
of thrombosis. The condition is readily detectable by
blood tests and, once diagnosed; the risk of further throm-
bosis can be significantly reduced by anticoagulation
treatments. Affected groups of patients can be distin-
guished by a specific blood test – the detection of
antiphospholipid antibody (Ref-1). Here we report the
case of a young woman presenting with acute, left-sided,
abdominal pain and upon investigation, she was found to
have splenic infarction. Haematological investigations
were positive for anticardiolipin antibodies, but negative
for coagulation risk factors for thrombosis. Interestingly
her subsequent determinations for anticardiolipin anti-
body were also negative. She was treated with anticoagu-
lation treatment. Patients with Hughes syndrome have
hypercoaguable state with a markedly increased risk of
both arterial and venous thrombosis and there is tempo-
ral persistence of antibody positivity.
Case presentation
A 44-year-old woman was admitted under the acute surgi-
cal "take" with left sided abdominal pain radiating to her
back. She worked as a dental hygienist and lived with her
husband and two children. She smoked 15 cigarettes a day
and there was no previous history of venous thrombosis.
She had a history of borderline thyrotoxicosis in the early
1990s and underwent tension-free vaginal tape treatment
for stress incontinence in September 2003. She was on
etonogestrel-releasing implants for contraception. She
was very tender, locally, over the left side of the abdomen
but rebound tenderness was absent. Rectal examination
was unremarkable. Investigations showed haemoglobin
of 13.2 g/dl, white cell count of 19.9 10*9/L, and platelets
214 10*9/L with neutrophilia. Amylase and renal func-
tion tests were found to be normal. Liver function tests
were deranged with Gamma GT 244 u/l (twice normal).
An abdominal Ultrasound Scan suggested a possible
splenic infarction, which was confirmed by a CT scan of
her abdomen. Tests were carried out to investigate the
possibility of a post thrombotic state. Coagulation risk
factors for thrombosis were within the normal limits; Pro-
tein S 67 %(60–140), Protein C 103 %(72–146), Anti-
thrombin 3 110 %(80–120) and Activated P C Resistance
was 1.9(2.0–4.3). The Hams test was negative but the
Anticardiolipin antibody test was positive. IgM level was
52 (normal is up to 10) and IgG was 18.8 (normal is up
to 10). She also had border line APC Sensitivity 1.9 (2 to
4.3). Kaolin time 49 sec (70–120) Ktmix 64 sec (70–120),
thyroid function test revealed TSH 0.32 mu/L, fT4 20.2
pmol/L (10–25). Subsequent determination of Anticardi-
olipin antibody was negative. Her symptoms were settled
with the use of simple analgesia and she was discharged
home with long-term anticoagulation medication. The
INR target for long-term anticoagulation was aimed at >3.
Conclusion
This case presented to us as an acute abdominal pain. Sub-
sequent investigations revealed the presence of splenic
infarction. Coagulation risk factors for thrombosis proved
negative. Haematological investigations revealed the pres-
ence of anticardiolipin antibodies at the first instance but
subsequent determinations were negative. Hence, it mim-
icked Hughes syndrome initially but the criteria for tem-
poral persistence of anticardiolipin antibody was not
fulfilled. Antiphospholipid Syndrome (APS) represents a
hypercoaguable state with increased incidence of both
arterial and venous thrombosis. The characteristic features
include vascular thrombosis, pregnancy loss, presence of
antibodies, neurological disease, thrombocytopenia and
lividoreticularis. The antibodies are directed against phos-
pholipids proteins, and there is a linear association
between the tendency to clot and the level of phospholip-
ids antibodies (Ref-2). Most of the patients are young
women and potential risk factors are contraceptive pills,
smoking, and hormone treatment. The gender ratio is 9
females to 1 male. Antiphospholipid antibodies are found
in autoimmune disorders like Systemic Lupus Erythema-
tosus (SLE), certain types of thyroid disease, rheumatoid
arthritis, and vasculitis.
Patients taking medications such as Dilantin, Pheno-
thizines or Hydralazine may develop Antiphospholipid
Syndrome. Frequently antiphospholipid antibodies will
disappear once the medication has been stopped.
Antiphospholipid antibodies may also appear for a short
time during a viral infection but disappear soon after the
viral infection is completely resolved. Most often, how-
ever, antiphospholipid antibodies are found at the time a
patient has developed a blood clot and none of the previ-
ously mentioned causes could be found.
Main symptoms of Antiphospholipid Syndrome are cere-
brovascular symptoms; these can vary from mainly
migraines and transient ischaemic attacks to full-blown
strokes, memory loss, choreo-athetosis, myelopathy,
transverse myelitis and epilepsy. Cardiovascular involve-
ment; this includes the risk of fatal, and non-fatal, heart
attacks in young women because of inflammatory throm-
botic processes. Some patients develop accelerated athero-
matous disease and there is high prevalence of
echocardiographic valve problems.
Thrombotic complications; these can present with visceral
infarctions. In kidneys, micro thrombi can form and addi-
tionally there can be evidence of renal vein thrombosis.
Past case studies have shown a higher prevalence of renal
artery stenosis (26 %) in patients with APS who have dif-Publish with BioMed Central    and   every 
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ficult-to-control hypertension, than in a hypertensive
group with otherwise healthy potential renal donors (Ref-
8). APS is also found to be a cause of Budd chiari syn-
drome and Addison's disease, due to acute infarction of
adrenal glands, has also been reported. E. coli infections
and surgery can precipitate wide spread thrombosis in
these patients. One large study in the USA did CT scans on
215 patients with antiphospholipid syndrome and found
splenic infarction in only six patients (Ref-9).
Current therapies used to prevent recurrent thrombosis
are controversial. Anticoagulant treatment is a better
option than anti-aggregants alone but there is a risk of
bleeding with anticoagulant treatment necessitating the
need for frequent monitoring of the INR (International
normalized ratio) to measure the anticoagulant effect of
the warfarin, which concerns both patients and physi-
cians. Acute thrombosis is treated by heparin infusion fol-
lowed by warfarinisation. Utilising low-molecular-weight
heparin reduces the risk of thrombocytopenia. Most avail-
able data supports the long-term oral anticoagulation
treatment. Prospective studies suggested that an INR
between 2.0 – 2.8 might be an adequate prophylaxis level
for venous thrombosis while retrospective studies suggest
the need for a higher intensity anticoagulation treatment
to prevent recurrent arterial events. (Ref-4). This case was
an unusual surgical presentation of a thrombotic abnor-
mality as abdominal pain due to splenic infarction.
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